The Contribution of GWAS Loci in Familial Dyslipidemias
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Familial combined hyperlipidemia (FCH) is a complex and common familial dyslipidemia characterized by elevated total cholesterol and/or triglyceride levels with over five-fold risk of coronary heart disease. The genetic architecture and contribution of rare Mendelian and common variants to FCH susceptibility is unknown. In 53 Finnish FCH families, we genotyped and imputed nine million variants in 715 family members with DNA available. We studied the enrichment of variants previously implicated with monogenic dyslipidemias and/or lipid levels in the general population by comparing allele frequencies between the FCH families and population samples. We also constructed weighted polygenic scores using 212 lipid-associated SNPs and estimated the relative contributions of Mendelian variants and polygenic scores to the risk of FCH in the families. We identified, across the whole allele frequency spectrum, an enrichment of variants known to elevate, and a deficiency of variants known to lower LDL-C and/or TG levels among both probands and affected FCH individuals. The score based on TG associated SNPs was particularly high among affected individuals compared to non-affected family members. Out of 234 affected FCH individuals across the families, seven (3%) carried Mendelian variants and 83 (35%) showed high accumulation of either known LDL-C or TG elevating variants by having either polygenic score over the 90th percentile in the population. The positive predictive value of high score was much higher for affected FCH individuals than for similar sporadic cases in the population. FCH is highly polygenic, supporting the hypothesis that variants across the whole allele frequency spectrum contribute to this complex familial trait. Polygenic SNP panels improve identification of individuals affected with FCH, but their clinical utility remains to be defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a novel, first-in-class, oral small molecule that inhibits cholesterol synthesis by inhibiting the action of ATP citrate lyase, a cytosolic enzyme upstream of 3-hydroxy-3-methylglutarylcoenzyme A reductase [340].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [340]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983 · cited 1×
“To construct a polygenic lipid score, we catalogued and used 212 SNPs, representing either the lead SNPs for genome-wide significant associations to LDL-C or TG from GWA studies of these traits (171 SNPs), or SNPs catalogued in the Online Mendelian Inheritance in Man (OMIM) database as located in genes implicated in p…”
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443 · cited 1×
“Familial combined hyperlipidemia (FCH), classically defined by elevations in serum total cholesterol (TC), triglycerides (TG), or both, in two or more first degree relatives, displays a prevalence of greater than 1% in Western populations [1, 2].”
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Self-citationFamilial lipoprotein disorders in patients with premature coronary artery disease.
Genest, J. J., Martin-Munley, S. S., McNamara, J. R., Ordovas, J. M., Jenner, J., Myers, R. H., Silberman, S. R., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992) · Circulation · doi:10.1161/01.cir.85.6.2025 · Cited by 596 · cited 1×
“It is the most common familial risk factor for premature coronary heart disease (CHD), occurring in 11–14% of individuals with this condition, and raising by up to five-fold the CHD risk in first- and second-degree relatives of affected individuals [3, 4].”
Talmud, P. J., Shah, S., Whittall, R., Futema, M., Howard, P., Cooper, J. A., Harrison, S. C., Li, K., Drenos, F., Karpe, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62127-8 · Cited by 591 · cited 1×
“This emphasizes the polygenic nature of FCH and is in line with previous results with familial hypercholesterolemia demonstrating that this less prevalent syndrome has a polygenic component [9].”
Talmud, P. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.24.3039 · Cited by 365 · cited 1×
“APOA5 rs3135506, which predisposes to hypertriglyceridemia in homozygous form [12], was 1.”
The impact of low-frequency and rare variants on lipid levels
ENGAGE Consortium, Surakka, I., Horikoshi, M., Mägi, R., Sarin, A.-P., Mahajan, A., Lagou, V., Marullo, L., Ferreira, T., Miraglio, B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3300 · Cited by 351
Self-citationFAMILY STUDY OF SERUM LIPIDS AND LIPOPROTEINS IN CORONARY HEART-DISEASE
Nikkilä, E., & Aro, A. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91598-5 · Cited by 292 · cited 1×
“Familial combined hyperlipidemia (FCH), classically defined by elevations in serum total cholesterol (TC), triglycerides (TG), or both, in two or more first degree relatives, displays a prevalence of greater than 1% in Western populations [1, 2].”
Deitch, R. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91664-0 · Cited by 249
Forty-year trends in cardiovascular risk factors in Finland
Borodulin, K., Vartiainen, E., Peltonen, M., Jousilahti, P., Juolevi, A., Laatikainen, T., Mannisto, S., Salomaa, V., Sundvall, J., & Puska, P. (2015) · The European Journal of Public Health · doi:10.1093/eurpub/cku174 · Cited by 228 · cited 12×
“By genotyping rs7412 and imputing rs429358 we were able to determine the phenotyped apolipoprotein E isoform with a minimum accuracy of 95% (Table 2).”
InfluentialSelf-citationHypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152 · cited 1×
“Our study supports the hypothesis that FCH is a genetically heterogeneous disease, reflected by its heterogeneous lipid phenotype [18–20].”
The genetics of familial combined hyperlipidaemia
Brouwers, M. C. G. J., van Greevenbroek, M. M. J., Stehouwer, C. D. A., de Graaf, J., & Stalenhoef, A. F. H. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.15 · Cited by 109 · cited 2×
“Many of the enriched TG SNPs were located in genes known to contribute to hypertriglyceridemia, such as the APOA1-C3-A4-A5 cluster, showing the central role of genetically driven TG in FCH [7, 17].”
APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency
Calandra, S., Oliva, C. P., Tarugi, P., & Bertolini, S. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000217892.00618.54 · Cited by 103 · cited 1×
“Many of the enriched TG SNPs were located in genes known to contribute to hypertriglyceridemia, such as the APOA1-C3-A4-A5 cluster, showing the central role of genetically driven TG in FCH [7, 17].”
Pirinen, M., Donnelly, P., & Spencer, C. C. A. (2013) · The Annals of Applied Statistics · doi:10.1214/12-aoas586 · Cited by 97 · cited 1×
“01) [27], and the other statistical analyses were performed using R (version 3.”
Self-citationJohansen, C. T., Wang, J., Lanktree, M. B., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., Schwartz, S. M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226365 · Cited by 97 · cited 1×
“Additionally, following the logic of recent studies that have demonstrated the combined impact of multiple small effect variants (polygenic scores) on risk for familial hypercholesterolemia (FH) and other lipid disorders [8–11], we measured, in these families, the relative contributions of LDL-C and TG associated poly…”
Self-citationJarvik, G. P., Brunzell, J. D., Austin, M. A., Krauss, R. M., Motulsky, A. G., & Wijsman, E. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.11.1687 · Cited by 92 · cited 1×
“Our study supports the hypothesis that FCH is a genetically heterogeneous disease, reflected by its heterogeneous lipid phenotype [18–20].”
Voors‐Pette, C., & de Bruin, T. W. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00752-8 · Cited by 78 · cited 1×
“It is the most common familial risk factor for premature coronary heart disease (CHD), occurring in 11–14% of individuals with this condition, and raising by up to five-fold the CHD risk in first- and second-degree relatives of affected individuals [3, 4].”
Brunzell, J. D., Zambon, A., & Deeb, S. S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.008 · Cited by 72 · cited 1×
“cardiovascular effects of which are unclear but may be dependent on the underlying lipid phenotype [14, 15].”
Combined hyperlipidemia: familial but not (usually) monogenic
Brahm, A. J., & Hegele, R. A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000270 · Cited by 71 · cited 1×
“Despite attempts to identify rare high-impact variants underlying FCH, no such variant has explained a substantial proportion of the trait [6].”
Phenotype expression in familial combined hyperlipidemia
Porkka, K. V. K., Nuotio, I. O., Pajukanta, P., Ehnholm, C., Suurinkeroinen, L., Syvänne, M., Lehtimäki, T. J., Lahdenkari, A.-T., Lahdenperä, S., Ylitalo, K., et al. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00134-2 · Cited by 61 · cited 13×
“By genotyping rs7412 and imputing rs429358 we were able to determine the phenotyped apolipoprotein E isoform with a minimum accuracy of 95% (Table 2).”
InfluentialSelf-citationExome Sequencing in Suspected Monogenic Dyslipidemias
Stitziel, N. O., Peloso, G. M., Abifadel, M., Cefalu, A. B., Fouchier, S., Motazacker, M. M., Tada, H., Larach, D. B., Awan, Z., Haller, J. F., et al. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000776 · Cited by 56 · cited 1×
“Additionally, following the logic of recent studies that have demonstrated the combined impact of multiple small effect variants (polygenic scores) on risk for familial hypercholesterolemia (FH) and other lipid disorders [8–11], we measured, in these families, the relative contributions of LDL-C and TG associated poly…”
Vuorio, A. F., Aalto-Setälä, K., Koivisto, U.-M., Turtola, H., Nissen, H., Kovanen, P. T., Miettinen, T. A., Gylling, H., Oksanen, H., & Kontula, K. (2001) · Annals of Medicine · doi:10.3109/07853890108995954 · Cited by 55 · cited 1×
“In the Finnish population there are five major extensively documented, FH-associated LDLR variants [16].”
Mining the genome for lipid genes
Kuivenhoven, J. A., & Hegele, R. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.028 · Cited by 52
A HEPATIC LIPASE GENE MUTATION ASSOCIATED WITH HERITABLE LIPOLYTIC DEFICIENCY
Hegele, R. A., Vézina, C., Moorjani, S., Lupien, P. J., Gagné, C., Brun, L., Little, J. A., & Connelly, P. W. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-3-730 · Cited by 51 · cited 1×
“cardiovascular effects of which are unclear but may be dependent on the underlying lipid phenotype [14, 15].”
Familial combined hyperlipidemia: from molecular insights to tailored therapy
van Greevenbroek, M. M. J., Stalenhoef, A. F. H., Graaf, J. D., & Brouwers, M. C. G. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000068 · Cited by 33
Zhao, S., Smelt, A. H. M., van den Maagdenberg, A. M. J. M., van Tol, A., Vroom, T. F. F. P., Leuven, J. A. G., van Tol, A., & Hooft, F. M. V. '. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.8.1559 · Cited by 11 · cited 1×
“The APOE ε2ε2 haplotype that predisposes to type III hyperlipoproteinemia [13], was observed in three FCH family members (two of them affected), all with elevated cholesterol and TG concentrations in very low-density lipoprotein and intermediate-density lipoprotein fractions (Table 2).”
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“FCH has no monogenic component and is not linked to a single genetic cause, but the phenotype is high LDL-C and/or high TGs.(358,359) Therefore, the diagnosis is commonly missed in clinical practice; the combination of ApoB >120 mg/dL and TGs >1.”
Self-citationA decade of genome-wide association studies for coronary artery disease: the challenges ahead
Erdmann, J., Kessler, T., Munoz Venegas, L., & Schunkert, H. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy084 · Cited by 325
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals
Natarajan, P., Peloso, G. M., Zekavat, S. M., Montasser, M., Ganna, A., Chaffin, M., Khera, A. V., Zhou, W., Bloom, J. M., Engreitz, J. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05747-8 · Cited by 183
Self-citationGenetic architecture of human plasma lipidome and its link to cardiovascular disease
Tabassum, R., Rämö, J. T., Ripatti, P., Koskela, J. T., Kurki, M., Karjalainen, J., Palta, P., Hassan, S., Nunez-Fontarnau, J., Kiiskinen, T. T. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11954-8 · Cited by 175
Self-citation
Metadata
- Authors
- Ripatti, P., Rämö, J. T., Söderlund, S., Surakka, I., Matikainen, N., Pirinen, M., Pajukanta, P., Sarin, A.-P., Service, S. K., Laurila, P.-P., Ehnholm, C., Salomaa, V., Wilson, R. K., Palotie, A., Freimer, N. B., Taskinen, M.-R., & Ripatti, S.
- Affiliations
- University of Helsinki (FI)
- Broad Institute (US)
- University of California, Los Angeles (US)
- Finnish Institute for Health and Welfare (FI)
- Washington University in St. Louis (US)
- Corresponding author
- Ripatti, Samuli
- ORCID
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-26
- Volume
- 12
- Issue
- 5
- Pages
- e1006078
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC4882070
- OpenAlex
- W2289474097
- Cited by
- 60
- References
- 30
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 1 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 10 · 2018: 10 · 2017: 4 · 2016: 2
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Työväentutkimus Vuosikirja (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- National Institutes of Health (HL113315, HL095056, HL28481)
- Sydäntutkimussäätiö
- Sigrid Juséliuksen Säätiö
- Biocentrum Helsinki
- EU 7th Framework Program (305707)
- Helsinki University Central Hospital Fund
- University of Helsinki Jubilee Fund
- Helsingin Yliopisto
- Suomen Lääketieteen Säätiö
- Emil Aaltosen Säätiö
- Biomedicum Helsinki-säätiö
- Suomen Akatemia (251217)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- familial combined hyperlipidemia, familial dyslipidemia, polygenic risk score, allele frequency spectrum, triglycerides, LDL cholesterol, genetic architecture, coronary heart disease risk, Finnish families
- MeSH terms
- Adult, Apolipoproteins B, Coronary Artery Disease, Female, Humans, Hyperlipidemia, Familial Combined, Cholesterol, HDL, Lipoproteins, LDL, Male, Middle Aged, Triglycerides, Dyslipidemias, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.